{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:02:00Z","timestamp":1790712120649,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jaad.org","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jaad.2018.12.031","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T19:44:29Z","timestamp":1545421469000},"page":"1746-1752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["The uses of naltrexone in dermatologic conditions"],"prefix":"10.1016","volume":"80","author":[{"given":"Brigette","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"Elston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.12.031_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jdcr.2018.07.002","article-title":"Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone","volume":"4","author":"Kollman","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2018.12.031_bib3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jamadermatol.2017.5463","article-title":"Variable response to naltrexone in patients with Hailey-Hailey disease","volume":"154","author":"Cao","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib4","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/bjd.16045","article-title":"Low-dose naltrexone: a novel treatment for Hailey-Hailey disease","volume":"178","author":"Campbell","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib5","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamadermatol.2017.2445","article-title":"Low-dose naltrexone treatment of familial benign pemphigus (Hailey-Hailey disease)","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib6","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jamadermatol.2017.2446","article-title":"Treatment of Hailey-Hailey disease with low-dose naltrexone","volume":"153","author":"Albers","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib7","doi-asserted-by":"crossref","first-page":"804296","DOI":"10.1155\/2011\/804296","article-title":"Low-dose naltrexone for pruritus in systemic sclerosis","volume":"2011","author":"Frech","year":"2011","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib8","first-page":"1140","article-title":"Novel treatment using low-dose naltrexone for lichen planopilaris","volume":"16","author":"Strazzulla","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib9","first-page":"270","article-title":"Compound low-dose naltrexone for the treatment of guttate psoriasis: a case report","volume":"22","author":"Muller","year":"2018","journal-title":"Int J Pharm Compd"},{"key":"10.1016\/j.jaad.2018.12.031_bib10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jdcr.2018.06.001","article-title":"Treatment of psoriasis vulgaris using low-dose naltrexone","volume":"4","author":"Bridgman","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2018.12.031_bib11","doi-asserted-by":"crossref","first-page":"e12720","DOI":"10.1111\/dth.12720","article-title":"Successful treatment of dermatomyositis with low-dose naltrexone","author":"Tran","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2018.12.031_bib12","series-title":"Incorporating Alcohol Pharmacotherapies Into Medical Practice","year":"2009"},{"key":"10.1016\/j.jaad.2018.12.031_bib13","article-title":"Low-dose naltrexone (LDN)-review of therapeutic utilization","volume":"6","author":"Toljan","year":"2018","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.jaad.2018.12.031_bib14","first-page":"857","article-title":"Ultra-low-dose naloxone or naltrexone to improve opioid analgesia: the history, the mystery and a novel approach","volume":"2","author":"Burns","year":"2010","journal-title":"Clin Med Insights Ther"},{"key":"10.1016\/j.jaad.2018.12.031_bib15","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","article-title":"Low-dose naltrexone therapy improves active Crohn's disease","volume":"102","author":"Smith","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2018.12.031_bib16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/phar.2086","article-title":"The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders","volume":"38","author":"Patten","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaad.2018.12.031_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5021\/ad.2016.28.2.159","article-title":"Clinical efficacy and safety of naltrexone combination therapy in older patients with severe pruritus","volume":"28","author":"Lee","year":"2016","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib18","series-title":"Itch: Mechanisms and Treatment","article-title":"Peripheral opioids","author":"Bigliardi","year":"2014"},{"key":"10.1016\/j.jaad.2018.12.031_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0165-0173(01)00160-6","article-title":"The biology of the opioid growth factor receptor","volume":"38","author":"Zagon","year":"2002","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.jaad.2018.12.031_bib20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/exd.13021","article-title":"Opioids and skin homeostasis, regeneration and ageing\u2014What's the evidence?","volume":"25","author":"Bigliardi","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2007.01.007","article-title":"Treatment of pruritus with topically applied opiate receptor antagonist","volume":"56","author":"Bigliardi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000082563","article-title":"Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis","volume":"210","author":"Bigliardi-Qi","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.12.031_bib23","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.bbrc.2005.10.072","article-title":"Detection of kappa and delta opioid receptors in skin\u2014outside the nervous system","volume":"338","author":"Salemi","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaad.2018.12.031_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2340\/00015555-1353","article-title":"Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2018.12.031_bib25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1081\/RRS-120014595","article-title":"Specific stimulation of migration of human keratinocytes by mu-opiate receptor agonists","volume":"22","author":"Bigliardi","year":"2002","journal-title":"J Recept Signal Transduct Res"},{"issue":"3","key":"10.1016\/j.jaad.2018.12.031_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000079887","article-title":"Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin","volume":"209","author":"Bigliardi-Qi","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.12.031_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bph.12687","article-title":"Activation of the \u03b4-opioid receptor promotes cutaneous would healing by affecting keratinocyte intercellular adhesion and migration","volume":"172","author":"Bigliardi","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaad.2018.12.031_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/wound.2016.0725","article-title":"Topical naltrexone is a safe and effective alternative to standard treatment of diabetic wounds","volume":"6","author":"McLaughlin","year":"2017","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"10.1016\/j.jaad.2018.12.031_bib29","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/1535370217724791","article-title":"Featured Article: serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone","volume":"242","author":"Ludwig","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jaad.2018.12.031_bib30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/1523-1747.ep12343712","article-title":"The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis","volume":"106","author":"Zagon","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib31","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1258\/ebm.2010.010203","article-title":"Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors","volume":"235","author":"McLaughlin","year":"2010","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jaad.2018.12.031_bib32","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1158\/1078-0432.CCR-04-0193","article-title":"Imiquimod treatment induces expression of opioid growth factor receptor- a novel tumor antigen induced by interferon-alpha?","volume":"10","author":"Urosevic","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2018.12.031_bib33","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/1352458508095828","article-title":"A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis","volume":"14","author":"Gironi","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.jaad.2018.12.031_bib34","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1177\/1535370214543061","article-title":"Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing","volume":"239","author":"Immonen","year":"2014","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jaad.2018.12.031_bib35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1523-1747.2002.01847.x","article-title":"Human keratinocytes express functional CD14 and toll-like receptor 4","volume":"119","author":"Song","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.12.031_bib37","series-title":"Revia (naltrexone hydrochloride tablets USP) [package insert]","year":"2013"},{"key":"10.1016\/j.jaad.2018.12.031_bib38","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1530-0277.2007.00593.x","article-title":"Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics","volume":"32","author":"Lucey","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jaad.2018.12.031_bib39","author":"Springer"},{"key":"10.1016\/j.jaad.2018.12.031_bib40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2018.12.031_bib41","article-title":"Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis","volume":"2","author":"Ludwig","year":"2016","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.jaad.2018.12.031_bib42","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","article-title":"Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial","volume":"56","author":"Smith","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaad.2018.12.031_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","article-title":"A comprehensive review and update on Crohn's disease","volume":"64","author":"Gajendran","year":"2018","journal-title":"Dis Mon"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218331049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218331049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T22:00:33Z","timestamp":1557957633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218331049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0190962218331049"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.12.031","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The uses of naltrexone in dermatologic conditions","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}